Karan Kanhai

IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study

Giuseppe Gritti, Federico Raimondi, Diego Ripamonti et al. · 2020 · 170 citations · Full text

Clinical Immunology, Inflammatory Lung Disease, Lung Inflammation +26

Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials

Frits van Rhee, Corey Casper, Peter M. Voorhees et al. · The Lancet Haematology · 2020 · 49 citations · Full text

Surgical Pathology, Pathology, Extension Analysis +3

Effect of L-NAME, an Inhibitor of Nitric Oxide Synthesis, on Cardiopulmonary Function in Human Septic Shock

J.A. Avontuur, Rudolf P. Tutein Nolthenius, S. L. C. E. Buijk et al. · CHEST Journal · 1998 · 41 citations

Acute Lung Injury, Cardiogenic Shock, Pulmonary Circulation +10

PULMONARY HYPERTENSION AND REDUCED CARDIAC OUTPUT DURING INHIBITION OF NITRIC OXIDE SYNTHESIS IN HUMAN SEPTIC SHOCK

J.A. Avontuur, Martine Biewenga, S. L. C. E. Buijk et al. · Shock · 1998 · 36 citations

Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease

Frits van Rhee, Adam Rosenthal, Karan Kanhai et al. · Blood Advances · 2022 · 35 citations · Full text

Lymphoid Neoplasia, Translational Medicine, Improved Progression-free Survival +15